Blog
RSS FeedPosted by Michael Wonder on 17 May 2024
Efanesoctocog alfa for the treatment and prevention of bleeding episodes in patients with haemophilia A
17 May 2024 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 16 May 2024
Tisagenlecleucel for the treatment of patients with relapsed or refractory B-cell acute lymphoblastic leukaemia
15 May 2024 - NICE has published final evidence-based recommendations on the use of tisagenlecleucel (Kymriah) for the treatment of ...
Posted by Michael Wonder on 16 May 2024
Acceptability of using real world data to estimate relative treatment effects in health technology assessments: barriers and future steps
15 May 2024 - Evidence about the comparative effects of new treatments is typically collected in randomised controlled trials (RCTs). In ...
Posted by Michael Wonder on 16 May 2024
Selinexor in combination with bortezomib and dexamethasone for the treatment of patients with relapsed/refractory multiple myeloma (final guidance)
15 May 2024 - NICE has published final evidence-based recommendations on the use of selinexor (Nexpovio) in combination with bortezomib ...
Posted by Michael Wonder on 15 May 2024
Atogepant monohydrate for the prevention of migraine
15 May 2024 - NICE has published final evidence-based recommendations on atogepant monohydrate (Aquipta) for preventing migraine in adults. ...
Posted by Michael Wonder on 13 May 2024
First ever life-saving treatment for rare heart condition available on the NHS
13 May 2024 - NHS patients with a life-threatening heart condition are set to benefit from a cutting-edge new medicine ...
Posted by Michael Wonder on 13 May 2024
Remdesivir and the combination of tixagevimab and cilgavimab for the treatment of patients with COVID-19 disease (final guidance)
8 May 2024 - NICE has published final evidence-based recommendations on the use of remdesivir (Veklury) and tixagevimab and cilgavimab ...
Posted by Michael Wonder on 10 May 2024
Tests could lead to fewer people having unnecessary chemotherapy after surgery for early breast cancer
10 May 2024 - More people with early breast cancer could be spared chemotherapy and therefore avoid the side effects associated ...
Posted by Michael Wonder on 08 May 2024
Selinexor with dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma after 4 or more treatments
8 May 2024 - NICE has published evidence-based recommendations on the use of selinexor (Nexpovio) in combination with dexamethasone for ...
Posted by Michael Wonder on 03 May 2024
Improved deal signals NICE recommendation of sickle cell treatment voxelotor
3 May 2024 - Around 4,000 people with sickle cell disease could benefit from a new treatment recommended by NICE ...
Posted by Michael Wonder on 03 May 2024
NHS rolls out ‘life-changing’ treatment for thousands with sickle cell disease
3 May 2024 - Thousands of patients with sickle cell disorder are to be offered a new “life-changing” treatment on ...
Posted by Michael Wonder on 01 May 2024
Selpercatinib for the treatment of patients with advanced thyroid cancer with RET alterations that has not been treated with systemic therapy
1 May 2024 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 01 May 2024
Pembrolizumab for the treatment of patients 3 years and older with relapsed or refractory classical Hodgkin's lymphoma
1 May 2024 - NICE has published updated evidence-based recommendations on the pembrolizumab (Keytruda) for the treatment of patients with ...
Posted by Michael Wonder on 30 Apr 2024
Gefapixant for the treatment of patients with refractory or unexplained chronic cough
30 April 2024 - NICE is unable to make a recommendation on the use of gefapixant (Lyfnua) for the treatment of ...
Posted by Michael Wonder on 29 Apr 2024
Idebenone for the treatment of patients 12 years and older with visual impairment associated with Leber’s hereditary optic neuropathy
24 April 2024 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...